Glenview Trust Co Purchases 15,559 Shares of Humana Inc. $HUM

Glenview Trust Co increased its position in Humana Inc. (NYSE:HUM) by 40.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 53,692 shares of the insurance provider’s stock after buying an additional 15,559 shares during the period. Glenview Trust Co’s holdings in Humana were worth $13,752,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of HUM. Montag A & Associates Inc. boosted its holdings in Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after buying an additional 94 shares during the period. CoreCap Advisors LLC lifted its stake in Humana by 54.4% in the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 37 shares in the last quarter. Rosenberg Matthew Hamilton lifted its stake in Humana by 136.0% in the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after purchasing an additional 68 shares in the last quarter. Larson Financial Group LLC lifted its stake in Humana by 114.1% in the 3rd quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider’s stock worth $40,000 after purchasing an additional 81 shares in the last quarter. Finally, Fulcrum Asset Management LLP purchased a new stake in Humana in the 3rd quarter worth $42,000. Institutional investors own 92.38% of the company’s stock.

Humana Stock Down 0.1%

Shares of NYSE HUM opened at $307.79 on Monday. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. Humana Inc. has a 12-month low of $163.11 and a 12-month high of $315.66. The firm’s 50-day moving average price is $218.13 and its 200-day moving average price is $227.27. The stock has a market capitalization of $36.95 billion, a price-to-earnings ratio of 32.92, a P/E/G ratio of 2.86 and a beta of 0.68.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. Humana had a net margin of 0.82% and a return on equity of 10.45%. The firm had revenue of $39.65 billion during the quarter, compared to the consensus estimate of $39.37 billion. During the same quarter last year, the firm earned $11.58 EPS. The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000- EPS. On average, equities research analysts anticipate that Humana Inc. will post 9.01 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. Humana’s dividend payout ratio (DPR) is presently 37.86%.

Analyst Upgrades and Downgrades

HUM has been the topic of several research analyst reports. Wells Fargo & Company cut shares of Humana from a “cautious” rating to a “reduce” rating in a research note on Wednesday. Morgan Stanley boosted their price target on shares of Humana from $146.00 to $217.00 and gave the stock an “underweight” rating in a research note on Friday, May 15th. Truist Financial boosted their price target on shares of Humana from $220.00 to $270.00 and gave the stock a “hold” rating in a research note on Thursday, April 30th. The Goldman Sachs Group boosted their price target on shares of Humana from $158.00 to $195.00 and gave the stock a “sell” rating in a research note on Thursday, April 30th. Finally, Jefferies Financial Group upgraded shares of Humana from a “buy” rating to a “buy” rating in a research note on Wednesday. Nine analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $263.35.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.